Cambridge's Addenbrooke's Hospital — an internationally recognised cancer and haematology centre — manages multiple myeloma patients requiring Lenalidomide-based therapy. Lenalid 25mg provides Cambridge patients with significant cost savings following patent expiry while delivering identical therapeutic benefit.
Cambridge's research-active myeloma programme means patients here often receive cutting-edge combination regimens incorporating Lenalidomide. For international patients attending Cambridge's private oncology services, generic Lenalid provides substantial savings over branded UK pricing.
Visit medshopy.com or WhatsApp +91 82650 41513.
Cambridge's research-active myeloma programme means patients here often receive cutting-edge combination regimens incorporating Lenalidomide. For international patients attending Cambridge's private oncology services, generic Lenalid provides substantial savings over branded UK pricing.
Visit medshopy.com or WhatsApp +91 82650 41513.
What is MRD testing in multiple myeloma and how does it affect treatment decisions?Minimal Residual Disease (MRD) testing uses highly sensitive molecular techniques to detect any remaining myeloma cells after treatment, even when standard blood tests and bone marrow biopsies appear normal. Cambridge haematologists are actively investigating how MRD status should guide treatment decisions — for example, whether patients who achieve MRD negativity might safely stop or reduce maintenance Lenalidomide earlier, reducing long-term side effects. MRD negativity is increasingly recognised as a powerful predictor of long-term remission, and it's shaping the future direction of myeloma treatment protocols.